Literature DB >> 902449

Clinical pharmacokinetics of digitoxin.

D Perrier, M Mayersohn, F I Marcus.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 902449     DOI： 10.2165/00003088-197702040-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  58 in total

1.  Blood level studies of C14-digitoxin in human subjects with cardiac failure.

Authors:  G T OKITA; P J TALSO; J H CURRY; F D SMITH; E M GEILING
Journal:  J Pharmacol Exp Ther       Date:  1955-04       Impact factor: 4.030

2.  Nonradioactive serum digoxin and digitoxin levels.

Authors:  W Shapiro; K Taubert; K Narahara
Journal:  Arch Intern Med       Date:  1972-07

3.  An improved method of digitoxin therapy.

Authors:  R W Jelliffe; J Buell; R Kalaba; R Sridhar; R Rockwell; J G Wagner
Journal:  Ann Intern Med       Date:  1970-04       Impact factor: 25.391

4.  Interactions between digitoxin and other drugs in vitro and in vivo.

Authors:  H M Solomon; S Reich; N Spirt; W B Abrams
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

5.  Large-scale digitoxin intoxication.

Authors:  A H Lely; C H van Enter
Journal:  Br Med J       Date:  1970-09-26

6.  Fate of orally administered 3H-digitoxin in man with special reference to the absorption.

Authors:  B Beermann; K Hellström; A Rosén
Journal:  Circulation       Date:  1971-06       Impact factor: 29.690

7.  Plasma protein binding of digitoxin and digoxin in several mammalian species.

Authors:  J D Baggot; L E Davis
Journal:  Res Vet Sci       Date:  1973-07       Impact factor: 2.534

8.  An improved method for measuring plasma and tissue concentrations of digitalis glycosides.

Authors:  J M Lowenstein; E M Corrill
Journal:  J Lab Clin Med       Date:  1966-06

9.  The measurement of digitoxin in human serum by radioimmunoassay.

Authors:  G C Oliver; B M Parker; D L Brasfield; C W Parker
Journal:  J Clin Invest       Date:  1968-05       Impact factor: 14.808

10.  Interruption of the enterohepatic circulation of digitoxin by cholestyramine. I. Protection against lethal digitoxin intoxication.

Authors:  J H Caldwell; N J Greenberger
Journal:  J Clin Invest       Date:  1971-12       Impact factor: 14.808
View more
  14 in total

Review 1.  Drug interactions with digitalis glycosides.

Authors:  P F Binnion
Journal:  Drugs       Date:  1978-05       Impact factor: 9.546

2.  Pharmacokinetics and bioavailability of digitoxin by a specific assay.

Authors:  R T MacFarland; F I Marcus; P E Fenster; P E Graves; D Perrier
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.

Authors:  J L Anderson; D C Harrison; P J Meffin; R A Winkle
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

4.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

5.  Pharmacokinetics and pharmacodynamics of intravenous digoxin and digitoxin.

Authors:  H R Ochs; E Grube; D J Greenblatt; R Arendt; G Bodem
Journal:  Klin Wochenschr       Date:  1981-08-17

Review 6.  Cardiac glycosides. Drug interactions of clinical significance.

Authors:  B Magnani; P L Malini
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

7.  Relationship between dose and plasma level of digoxin and patient characteristics.

Authors:  N Heinz; N Rietbrock
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

8.  Digitoxin accumulation.

Authors:  H R Ochs; J Pabst; D J Greenblatt; J Hartlapp
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

9.  Pharmacodynamics, pharmacokinetics and metabolism of digitoxin and derivatives in cats.

Authors:  I Bauer; P Neubert; W Schaumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

10.  Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.

Authors:  J Fabre; H M Fox; P Dayer; L Balant
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.